Teva Photo: ASAP Creative Shutterstock Analysts soothe on Teva's migraine drug snub

Teva's Ajovy may have been rejected by Express Scripts for reimbursement but other US health insurers will accept it, say the analysts.

Julian Adams Photo: PR Novartis to invest in $60m Gamida Cell Nasdaq IPO

The Israeli stem cell cancer therapy developer will hold the offering at a company valuation of $275 million.

Teva Photo: Reuters Ammar Awad Teva falls on migraine drug indemnity snub

Express Scripts has endorsed coverage of competing migraine drugs made by Amgen and Eli Lilly.

Medical cannabis Photo: Shutterstock Cannabis R&D lab set up at Hebrew University

The Asana Bio Group Israeli holding company has invested $2.3 million in founding a laboratory for research on the active ingredients in the cannabis plant.

Shimon Eckhouse Heart valve co Trisol Medical raises $2.7m

The Israeli company, which has developed a minimally invasive way to replace the tricuspid heart valve, is aiming at a $6 billion market.

Leon Koffler  photo: PR Amir Marketing, Leon Koffler investing in BOL Pharma

BOL produces and markets cannabis for the Israeli market.

Copaxone Teva loses another Copaxone patents case

The US Court of Appeals for the Federal Circuit upheld a 2017 decision by a Delaware court canceling four patents on the 40 mg version of Teva's blockbuster multiple sclerosis treatment.

Dr Anat Cohen-Dayag Photo: Kfir Ziv BMS invests $12m in Compugen for tumor collaboration

The companies have entered into a clinical trial collaboration to evaluate Compugen’s COM701 with BMS's PD-1 immune checkpoint inhibitor Opdivo, in patients with advanced solid tumors.

Teva Photo: ASAP Creative Shutterstock Teva receives FDA nod for Rituxan biosimilar cancer drug

If the FDA approves CT-P10 for marketing, this will be the first biosimilar generic version of Rituxan.

Uwe Roehrhoff Photo: PR Perrigo appoints new CEO

Murray Kessler is replacing Uwe Roehrhoff, who lasted 10 months in the job.

Prof. Moshe Shoham Photo: Paul Orlive Mazor founder has more startups in the pipeline

Medtronic is buying Prof. Moshe Shoham's Mazor for $1.6 billion, while he is looking forward to more robots and more startups.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018